Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sapanisertib · 1 trial · 1 indication
Defined as the proportion of participants with measurable disease at baseline who have confirmed complete response (CR) or partial response (PR).
| Arm | Type | Description |
|---|---|---|
| sapanisertib and serabelisib (PIKTOR) with paclitaxel | EXPERIMENTAL | Subjects will receive doses of sapanisertib and serabelisib (PIKTOR) administered orally and paclitaxel administered intravenously. |
| Name | Type | Description |
|---|---|---|
| Sapanisertib | DRUG | Oral |
| Serabelisib | DRUG | Oral |
| Paclitaxel | DRUG | Infusion |
Inclusion Criteria: * Histologically confirmed diagnosis of endometrioid endometrial carcinoma. * Documented evidence of advanced or recurrent endometrial cancer that is not amenable to surgery/radiation for curative intent. * Participant has received at least 1 but not more than 4 prior systemic t...
Top 20 of 47 competitors
Sapanisertib is an investigational small molecule being studied for the treatment of advanced or recurrent endometrial cancer. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Sapanisertib is a small molecule that targets mTOR, a key protein involved in cell growth and proliferation. By inhibiting mTOR, it aims to slow or stop the growth of cancer cells in endometrial cancer.
Sapanisertib is being developed by Sensei Biotherapeutics, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with endometrial cancer.
Sapanisertib is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies and is still undergoing clinical trials to assess its safety and effectiveness.
Sapanisertib is being studied in a Phase 2 clinical trial with the identifier NCT06463028. This trial is recruiting patients with advanced or recurrent endometrial cancer and is being conducted in the United States.
Sapanisertib is also known as PIKTOR. In clinical trials, it is being studied in combination with serabelisib and paclitaxel, along with a substudy involving an insulin-suppressing diet, for the treatment of endometrial cancer.